Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3903 ARTÍCULOS , VIENDO DEL 2641 AL 2655

Mind the gap: models in multiple species needed for therapeutic development in Huntington's disease

Howland DS, Munoz-Sanjuan I.

Mov Disord. 2014 Sep 15;29(11):1397-403. doi: 10.1002/mds.26008. Epub 2014 Aug 22.

Chorea associated with Huntington's disease: to treat or not to treat?

Jankovic J, Roos RA.

Mov Disord. 2014 Sep 15;29(11):1414-8. doi: 10.1002/mds.25996. Epub 2014 Aug 22.

Amyotrophic lateral sclerosis: a focus on disease progression

Calvo AC, Manzano R, Mendonça DM, Muñoz MJ, Zaragoza P, Osta R.

Biomed Res Int. 2014;2014:925101. doi: 10.1155/2014/925101. Epub 2014 Aug 3.

Magnetic resonance imaging striatal volumes: a biomarker for clinical trials in Huntington's disease

Aylward EH.

Mov Disord. 2014 Sep 15;29(11):1429-33. doi: 10.1002/mds.26013. Epub 2014 Aug 27.

Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?

Killoran A, Biglan KM.

Mov Disord. 2014 Sep 15;29(11):1404-13. doi: 10.1002/mds.26014. Epub 2014 Aug 27.

Antioxidative defense mechanisms controlled by Nrf2: state-of-the-art and clinical perspectives in neurodegenerative diseases

Lim JL, Wilhelmus MM, de Vries HE, Drukarch B, Hoozemans JJ, van Horssen J.

Arch Toxicol. 2014 Oct;88(10):1773-86. doi: 10.1007/s00204-014-1338-z. Epub 2014 Aug 28.

Huntingtin-lowering strategies in Huntington's disease: antisense oligonucleotides, small RNAs, and gene editing

Aronin N, DiFiglia M.

Mov Disord. 2014 Sep 15;29(11):1455-61. doi: 10.1002/mds.26020. Epub 2014 Aug 27.

Insights into gait disorders: walking variability using phase plot analysis, Huntington's disease

Collett J, Esser P, Khalil H, Busse M, Quinn L, DeBono K, Rosser A, Nemeth AH, Dawes H.

Gait Posture. 2014 Sep;40(4):694-700. doi: 10.1016/j.gaitpost.2014.08.001. Epub 2014 Aug 10.

Ghrelin: a link between ageing, metabolism and neurodegenerative disorders

Stoyanova II.

Neurobiol Dis. 2014 Dec;72 Pt A:72-83. doi: 10.1016/j.nbd.2014.08.026. Epub 2014 Aug 27.

Participation of group I p21-activated kinases in neuroplasticity

Koth AP, Oliveira BR, Parfitt GM, Buonocore Jde Q, Barros DM.

J Physiol Paris. 2014 Sep-Dec;108(4-6):270-7. doi: 10.1016/j.jphysparis.2014.08.007. Epub 2014 Aug 28.

Adenosine receptors and Huntington's disease

Lee CF, Chern Y.

Int Rev Neurobiol. 2014;119:195-232. doi: 10.1016/B978-0-12-801022-8.00010-6.

Adenosine receptor control of cognition in normal and disease

Chen JF.

Int Rev Neurobiol. 2014;119:257-307. doi: 10.1016/B978-0-12-801022-8.00012-X.

Cognitive function in early clinical phase huntington disease after rivastigmine treatment

Sešok S, Bolle N, Kobal J, Bucik V, Vodušek DB.

Psychiatr Danub. 2014 Sep;26(3):239-48.

Delayed Onset of Chorea After Extrapontine Myelinolysis

Cury RG, Caldas VM, Dornelas GO Jr, Haddad MS.

Mov Disord Clin Pract. 2014 Sep 9;1(4):366-367. doi: 10.1002/mdc3.12051. eCollection 2014 Dec.

The mechanism of degeneration of striatal neuronal subtypes in Huntington disease

Rikani AA, Choudhry Z, Choudhry AM, Rizvi N, Ikram H, Mobassarah NJ, Tulli S.

Ann Neurosci. 2014 Jul;21(3):112-4. doi: 10.5214/ans.0972.7531.210308.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias